Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PBLA

PBLA - Panbela Therapeutics Inc. Stock Price, Fair Value and News

$0.01+0.01 (+Infinity%)
Market Closed

Price Targets

PBLA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PBLA Price Action

Last 90 days

-100%

Trailing 12 Months

-100%

PBLA RSI Chart

PBLA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PBLA Valuation

EV/EBITDA

-0.11

PBLA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

PBLA Fundamentals

PBLA Revenue

PBLA Earnings

PBLA Profitability

PBLA Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20180000
201703.0K2.0K1.0K
20167.0K5.0K5.0K4.0K
20150008.0K
20140000
20131.2M1.1M1.0M973.8K
20120001.2M
2011000699.8K
Get all data in R, Python etc through our Historical Stock Data APIs

About Panbela Therapeutics Inc.

PBLA
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with cancer. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin (SBP-101). The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
 CEO
 WEBSITEpanbela.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES6

Panbela Therapeutics Inc. Frequently Asked Questions

PBLA is the stock ticker symbol of Panbela Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of Panbela Therapeutics Inc. is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PBLA's fair value in chart for subscribers.

The fair value guage provides a quick view whether PBLA is over valued or under valued. Whether Panbela Therapeutics Inc. is cheap or expensive depends on the assumptions which impact Panbela Therapeutics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PBLA.

As of Tue Jan 27 2026, PBLA's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PBLA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Panbela Therapeutics Inc. has provided -0.774 (multiply by 100 for percentage) rate of return.